Back to search results

Comparing Granisetron Patch to Ondansetron for Nausea and Vomiting During Chemotherapy

This study is comparing two medications, Granisetron Transdermal Patch and Ondansetron, to see which is more effective at preventing nausea and vomiting caused by chemotherapy. You might be able to join if you are between 18 and 75 years old and are undergoing chemotherapy before a stem cell transplant. The study is looking for 90 participants. We will know the treatment is successful if patients don't vomit and don't need extra nausea medication within the first 24 hours after chemotherapy. The current status of this study is unclear.

Study design
This is an open-label, randomized study, meaning you and your doctors will know which treatment you are receiving. About 90 participants will be randomly assigned to one of two treatment groups.
What's involved
If you are in the granisetron group, you will apply a patch 1-2 days before chemotherapy, and another patch 7 days later. Both groups will also receive intravenous (IV) dexamethasone.
Compensation
Not stated in the trial record.
Follow-up
The main goal of the study is measured during the acute period, which is 0-24 hours after chemotherapy.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04150614

BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron

Recruiting
PHASE4Ages 18–75InterventionalSupportive care
University of Illinois at Chicago
~90 participants
Updated 2025-11-12 on ClinicalTrials.gov
What's tested:Granisetron Transdermal PatchIntravenous DexamethasoneOndansetron

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To compare between the two study arms the number of patients achieving complete response (no vomiting and no use of rescue medications) during the acute period (0-24 hours post-chemotherapy) for patients receiving preparative chemotherapy and HSCT.
Measured over 0 hours to 24 hours post-chemotherapy

Conditions

Nausea With Vomiting Chemotherapy-Induced

Explore related trials

Chemotherapy-Related Nausea and/or VomitingHematopoietic Cell Transplantation

Where it's being run

1 sites across 1 states
Illinois1

Study leadership

  • Karen Sweiss, PharmD · PRINCIPAL_INVESTIGATOR · University of Illinois at Chicago

Who to contact

Karen Sweiss, PharmD
[email protected]
312-996-0875
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18-75 years at time of enrollment receiving either a preparative regimen and either an autologous or allogeneic stem cell transplant.
No vomiting ≤ 24 hours prior to registration
No treatment with an antipsychotic agent such as risperidone, quetiapine, clozapine, phenothiazine or butyrophenone for ≤ 30 days' prior registration or planned during protocol therapy. No patients will be removed from these treatments for study enrollment purposes.
No chronic phenothiazine administration as an antipsychotic agent (patients may receive prochlorperazine and other phenothiazines as rescue antiemetic therapy). No patients will be removed from these treatments for study enrollment purposes.
No known hypersensitivity to granisetron

Exclusion

Concurrent use of amifostine
Known hypersensitivity to granisetron patch or ondansetron
Patients with a history of long QT syndrome or Torsade de Pointes

What this trial measures

  • To compare between the two study arms the number of patients achieving complete response (no vomiting and no use of rescue medications) during the acute period (0-24 hours post-chemotherapy) for patients receiving preparative chemotherapy and HSCT.0 hours to 24 hours post-chemotherapy

    Efficacy of Ondansetron and Dexamethasone versus Transdermal Granisetron and Dexamethasone in preventing chemotherapy induced nausea and vomiting during the acute period (0 - 24 hours post-chemotherapy) for patients receiving preparative chemotherapy and HSCT.